Jonathan Schwartz, MD (@jgschwartzmd) 's Twitter Profile
Jonathan Schwartz, MD

@jgschwartzmd

Structural+Interventional Cardiologist | Med Dir of Int Card @AtriumSHVI | Asst Prof @wakeforestmed | @thepearlCLT | #IRCAD | @ACCintouch HC Innovation Council

ID: 567018579

linkhttp://linkedin.com/in/jgschwartzmd calendar_today30-04-2012 05:32:36

393 Tweet

787 Followers

842 Following

Nishtha Sodhi (@nishthasodhi) 's Twitter Profile Photo

#️⃣ 576 transcarotid & 1142 transaxillary pts ⏰Mdn prcdr (99 vs 118 mins; p<0.001) & 🏥 stay (2 vs 3 days; p<0.001) 🔻 TC vs TA 🗓️30 days TC similar ☠️ (KM 3.7% vs 4.3%, p=0.57) but sig ⬇️ stroke (3.1% vs 5.9%; p=0.017). Similar @ 1yr ✅ KeithAllen jtcvstechniques.org/article/S2666-…

#️⃣ 576 transcarotid &amp; 1142 transaxillary pts
⏰Mdn prcdr (99 vs 118 mins; p&lt;0.001) &amp; 🏥 stay (2 vs 3 days; p&lt;0.001) 🔻 TC vs TA 

🗓️30 days TC similar ☠️ (KM 3.7% vs 4.3%, p=0.57) but sig ⬇️ stroke (3.1% vs 5.9%; p=0.017). Similar @ 1yr ✅

KeithAllen jtcvstechniques.org/article/S2666-…
Jonathan Schwartz, MD (@jgschwartzmd) 's Twitter Profile Photo

LBCT #TCT2023 - Marty Leon 5yr #PARTNER3 low-risk RCT: ☑️ TAVR+SAVR low CV death/stroke/CV rehosp rates ☑️ TAVR benefits @ 1yr ⬇️ at 5yrs ☑️ TAVR: Less AF/bleeding, SAVR: less PVL/valve thrombosis ☑️ similar ppm, reint ☑️ similar gradients ☑️ infreq BVF/SVD ☑️ KCCQ maintained

LBCT #TCT2023 - <a href="/MartyBLeon/">Marty Leon</a> 5yr #PARTNER3 low-risk RCT:
☑️ TAVR+SAVR low CV death/stroke/CV rehosp rates
☑️ TAVR benefits @ 1yr ⬇️ at 5yrs
☑️ TAVR: Less AF/bleeding, SAVR: less PVL/valve thrombosis
☑️ similar ppm, reint
☑️ similar gradients
☑️ infreq BVF/SVD
☑️ KCCQ maintained
Jonathan Schwartz, MD (@jgschwartzmd) 's Twitter Profile Photo

#TMVR: the wait will be worth it - panel discussion: ➡️ scientific understanding, progress has been slow; long path ahead ➡️ value proposition is no MR post-op ➡️ MANY devices ▶️ difficultly enrolling patients ➡️ safety profile of TMVR devices is main hurdle PCRonline 🫀 Cardiovascular Research Foundation

#TMVR: the wait will be worth it - panel discussion:
➡️ scientific understanding, progress has been slow; long path ahead
➡️ value proposition is no MR post-op
➡️ MANY devices ▶️ difficultly enrolling patients
➡️ safety profile of TMVR devices is main hurdle
<a href="/PCRonline/">PCRonline 🫀</a> <a href="/crfheart/">Cardiovascular Research Foundation</a>
EAPCIPresident (@eapcipresident) 's Twitter Profile Photo

The #EAPCI community mourns the sudden loss of Alain Cribier, a pioneering #IC known for numerous 'firsts' including the first-in-man #TAVI on April 16, 2002. Our heartfelt condolences to his family, friends + colleagues. His wisdom, expertise and guidance will be greatly missed.

The #EAPCI community mourns the sudden loss of Alain Cribier, a pioneering #IC known for numerous 'firsts' including the first-in-man #TAVI on April 16, 2002. Our heartfelt condolences to his family, friends + colleagues. His wisdom, expertise and guidance will be greatly missed.
Jonathan Schwartz, MD (@jgschwartzmd) 's Twitter Profile Photo

One of the best sessions Omar any meeting all year (other meetings take note… conversations/commentary >>> recycled slides). #sif2024 conversations in cardiology with Morton J Kern. #cardiotwitter: thoughts on the topics below? Molly Szerlip MD David Rizik, MD Timothy Henry SIF 2025

One of the best sessions Omar any meeting all year (other meetings take note… conversations/commentary &gt;&gt;&gt; recycled slides). #sif2024 conversations in cardiology with <a href="/MortonKern/">Morton J Kern</a>. #cardiotwitter: thoughts on the topics below? <a href="/mszerlip/">Molly Szerlip MD</a> <a href="/RizikMd/">David Rizik, MD</a> <a href="/HenrytTimothy/">Timothy Henry</a> <a href="/SIFCardiology/">SIF 2025</a>
Wally A. Omar, MD (@wallyomarmd) 's Twitter Profile Photo

SESAME for LVOT reduction demonstrates amazing ⬇️ in septal thickness and ⬆️ in neoLVOT area. #CRT2024 Late breakers. Great safety profile compared to traditional invasive alternatives.

SESAME for LVOT reduction demonstrates amazing ⬇️ in septal thickness and ⬆️ in neoLVOT area. #CRT2024 Late breakers. Great safety profile compared to traditional invasive alternatives.
BostonSci Cardiology (@bsccardiology) 's Twitter Profile Photo

Congrats to Auroa Badin, David DeLurgio, Dr. Devi G Nair, Jonathan Schwartz, MD & Dr. Noah Thormeier for being first in their respective state to use the WATCHMAN TruSteer™ Access System! Check out their photos below👇 Safety info: bit.ly/3YP62GY

Jonathan Schwartz, MD (@jgschwartzmd) 's Twitter Profile Photo

It’s time… BostonSci Cardiology #Watchman #TruSteer access system finally available! Bidirectional tip articulation + less core wire bias ➡️ huge advance in the #LAAO world to optimize #watchmanFLXpro delivery. First case w/precise positioning 👌🏻 Dr. Devi G Nair Mohamad Alkhouli

It’s time… <a href="/BSCCardiology/">BostonSci Cardiology</a> #Watchman #TruSteer access system finally available! Bidirectional tip articulation + less core wire bias ➡️ huge advance in the #LAAO world to optimize #watchmanFLXpro delivery. First case w/precise positioning 👌🏻 <a href="/Drdevignair/">Dr. Devi G Nair</a> <a href="/adnanalkhouli/">Mohamad Alkhouli</a>
PCRonline 🫀 (@pcronline) 's Twitter Profile Photo

When should we start discussing interventional treatment for optimal results? What about valve selection? Will AI impact physician choices? Following the session on early diagnosis and lifetime management of valvular heart disease at #PCRLV, Marcio Montenegro asked Jonathan Schwartz, MD to

Soc. Chilena de Cardiología (@sochicaroficial) 's Twitter Profile Photo

Exposición del Dr. Jonathan Schwartz en módulo de Hemodinamia: "Tratamiento percutáneo de la válvula tricúspide". #CongresoSOCHICAR2024 #Hemodinamia

Exposición del Dr. Jonathan Schwartz en módulo de Hemodinamia: "Tratamiento percutáneo de la válvula tricúspide".

#CongresoSOCHICAR2024 #Hemodinamia